GAP

The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

Washington D.C., Nov. 26, 2024- The Centers for Medicare & Medicaid Services (CMS) released the Clinical Laboratory Fee Schedule (CLFS) 2025 Final Rate Determinations yesterday, unveiling that clinically critical codes for the reimbursement of Alzheimer neurological biomarker blood tests have been referred to the process known as “gapfill.” Earlier this year, the preliminary recommendation for […]

By ActionNewsJax.com News Staff, November 18, 2024 at 5:32 pm EST Jacksonville Center for Clinical Research just joined the Global Alzheimer’s Platform Foundation’s national network of research centers. According to a news release, the JCCR has conducted more than 1,000 clinical trials over 25 years. Global Alzheimer’s Platform President John Dwyer said the organization wants to […]

Washington D.C., Nov. 18, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming a new clinical research site into its international network of best-in-class research sites, Jacksonville Center for Clinical Research of Jacksonville, Florida. Jacksonville Center for Clinical Research (JCCR) is a premier clinical research site, having conducted more than 1,000 clinical trials over 25 years with […]

Contify Life Science News Nov 3 • 11:52 PM *Cognivue’s participation in the study will help predict underlying AD pathologies and analyze MRI, neuroinflammation, and longitudinal data. Oct. 30– Cognivue issued the following news release:. Its proven ability to distinguish between cognitively normal individuals, those with MCI, and mild dementia— regardless of amyloid status., Validated […]

By Robbie Owens, November 1, 2024 / 6:05 PM CDT / CBS Texas DALLAS – If you dare, just look at the numbers associated with Alzheimer’s: nearly 7 million Americans are diagnosed with the disease right now. According to the Alzheimer’s Association, the potential lifetime impact is 1 in 3. Gail Youngdale is one of them. “My mother […]

Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]

By Eleanore Catolico, 10/23/24 Renee Stamper, shown here with a portrait of her mother, has joined 15 clinical trials in eight years. (Photo by Alejandro Ugalde Sandoval)On Christmas Eve 2014, a speeding car clipped the bumper of a Detroit city bus in the early morning darkness. Renee Stamper, the bus driver, spun on the road.  After […]

2024, 10-21, Jason Shafrin That is the title of an interesting panel from USC Schaeffer Center on Coverage with Evidence Development (CED). It includes an interview with Tamara Syrek Jensen, Director, of the Coverage & Analysis Group within the Centers for Medicare & Medicaid Services. After the interview, there is a panel discussion of academics with […]

What we do Dementia and Neurodegeneration was identified as one of the key healthcare missions in the 2021 Life Sciences Vision. Dementia is the leading cause of death in England and one in two people will be directly affected by it – either they will care for someone with the condition, develop it themselves, or both. […]

Canton Repository The North Canton-based Ohio Center for Hope, in collaboration with Neuro-Behavioral Clinical Research, played host to a highly successful Memory Day + Senior Resource Fair on Sept. 14 at Firestone Park Community Center. The event provided free memory screenings, emphasized the critical importance of early memory-loss detection, provided valuable information for those experiencing […]

Partnership to Cultivate Best-In Class Clinical Research Services for Alzheimer’s disease and related dementias Washington D.C. – Sept 19, 2024 – Global Alzheimer’s Platform Foundation® (GAP) and the University of Nevada, Las Vegas (UNLV), announced a memorandum of understanding (MOU) regarding a collaboration to accelerate research for neurodegenerative diseases. This includes establishing a state-of-the-art imaging and emerging technology […]

Entities sign Memorandum of Understanding to cultivate best-in-class clinical research services for Alzheimer’s disease and other neurodegenerative diseases LAS VEGAS – Sept 19. – UNLV and the Global Alzheimer’s Platform Foundation (GAP) are joining forces to accelerate the development of new biomarker and diagnostic tests for Alzheimer’s and other central nervous system (CNS) diseases and […]

By Raya Torres, Published: Sep. 18, 2024 at 3:01 PM EDT TUCSON, Ariz. (13 News)—The Banner Alzheimer’s Institute hosted a senior health resource fair on Tuesday, Sept. 17, to increase awareness of brain health and Alzheimer’s prevention and awareness. According to the National Council on Aging, Latinos maybe 50% more likely to develop Alzheimer’s, but they are […]

By Axiom Brain Health We have all heard how important it is to eat well, exercise, and get enough sleep for good health, but did you know that there are additional ways you may improve your brain health? Learn about three unique ways you may reduce the risk of memory loss and/or may prevent the onset […]

by Zoe Holman, Fri, August 16th 2024 at 5:24 PM A global Alzheimer’s organization is expanding its research into southeast Texas. The global Alzheimer’s Platform Foundation is partnering with Gadolin Research. The Beaumont Medical Clinic joins more than 130 research centers worldwide that make up the G.A.P. network. The joint partnership centered on improving access to […]

An eye-based Alzheimer’s disease test Routine eye exams could provide data to identify a patient’s disease risk earlier Spotted: Dementia diagnoses appear to be increasing worldwide, most likely from a combination of ageing populations and improved awareness of the disease alongside strengthened diagnostic tools. In Canada, medical AI company RetiSpec uses commonly used eye exam images to diagnose Alzheimer’s […]

Cambridge, UK—10 July 2024: Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.  The Bio-Hermes 2 trial, led by the Global Alzheimer’s Platform Foundation (GAP), aims to determine […]

10 July 2024 Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis. The funding will enable organisations to evaluate blood-based and digital biomarkers as part of the Bio-Hermes-002 study. This international study is led by the Global Alzheimer’s Platform Foundation® […]

The Washington, D.C.-based Global Alzheimer’s Platform Foundation announced on July 8 that Snellville resident Tamiko MaGee-Rodgers has been named director of the foundation’s Recruitment and Strategic Initiatives. The nonprofit GAP was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research and lowering the cost and duration of […]

Washington D.C., July 8, 2024- Global Alzheimer’s Platform Foundation® (GAP) announced the appointment of Leigh Zisko, MPH as Chief Impact Officer and Tamiko MaGee-Rodgers, PhD, CCRP as the Director of Recruitment and Strategic Initiatives. In newly created global leadership roles, each will meaningfully contribute new perspectives and experience to GAP’s work in innovating clinical trial […]

Washington D.C., July 2, 2024- Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer applauds the U.S. Food and Drug Administration (FDA) for its decision granting full traditional approval of Eli Lilly and Company’s Kisunla™ (donanemab), a disease-modifying Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD).  “Today, the FDA grants full approval for donanemab, […]

Washington D.C., July 1, 2024- The Food and Drug Administration (FDA) unveiled a draft guidance document, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” which is open for public comment. This draft guidance points to improving participation from people who are traditionally underrepresented in clinical trials. John Dwyer, President […]